IL-6 blockade in systemic juvenile idiopathic arthritis

• Verfasst von: Bielak, Maria [VerfasserIn]
• Verfasst von: Lutz, Thomas [VerfasserIn]
• Titel: IL-6 blockade in systemic juvenile idiopathic arthritis
• Titelzusatz: achievement of inactive disease and remission (data from the German AID-registry)
• Verf.angabe: M. Bielak, E. Husmann, N. Weyandt, J.-P. Haas, B. Hügle, G. Horneff, U. Neudorf, T. Lutz, E. Lilienthal, T. Kallinich, K. Tenbrock, R. Berendes, T. Niehues, H. Wittkowski, E. Weißbarth-Riedel, G. Heubner, P. Oommen, J. Klotsche, Dirk Foell and E. Lainka
• E-Jahr: 2018
• Jahr: 05 April 2018
• Umfang: 8 S.
• Fussnoten: Gesehen am 20.08.2019
• Titel Quelle: Enthalten in: Pediatric rheumatology
• Ort Quelle: London : BioMed Central, 2003
• Jahr Quelle: 2018
• Band/Heft Quelle: 16(2018) Artikel-Nummer 22, 8 Seiten
• ISSN Quelle: 1546-0096
• DOI: doi:10.1186/s12969-018-0236-y
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1671648455

Abstract

Systemic juvenile idiopathic arthritis (sJIA) is a complex disease with an autoinflammatory component of unknown etiology related to the innate immune system. A major role in the pathogenesis has been ascribed to proinflammatory cytokines like interleukin-6 (IL-6), and effective drugs inhibiting their signaling are being developed. This study evaluates sJIA patients treated with the IL-6 inhibitor tocilizumab (TCZ) concerning clinical response rate, disease course and adverse effects in a real-life clinical setting.